Autopsy report · NCT00020683
A Phase II Trial of COL-3 in Patients With HIV Related Kaposi's Sarcoma
Cause of deathDrug or device supply
“Cancer Therapy Evaluation Program's (CTEP's) termination of drug supply”
Life of this trial
- Registered 1 year 8 months before it started.
- Ran for about 6 years 8 months before it stopped.
- 70 participants planned (an estimate, not an actual count).
- No results are posted on the registry.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2
- Sponsor
- National Cancer Institute (NCI)
- Sponsor type
- US National Institutes of Health
- Conditions
- AIDS-related Kaposi Sarcoma; HIV Infection
- Interventions
- incyclinide; incyclinide; laboratory biomarker analysis
- Participants
- 70 (planned, not actual)
- Sites
- 1
- Countries
- United States
Trials that died the same way
- Umbralisib and Pembrolizumab in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma
“Company providing drug terminated their oncology program” - A Study of the Safety and Pharmacokinetics of AGS-8M4 Given in Combination With Chemotherapy in Women With Ovarian Cancer
“Trial was terminated to allow sponsors to evaluate the future development of the drug program” - Pilot Study of Nivolumab in Pediatric Patients With Hypermutant Cancers
“Withdrawal of drug supply/funding” - First-in-Human Study of TAK-280 in Participants With Solid Tumors
“Terminated due to limited anti-cancer activity” - CIVO Intratumoural Microdosing of Anti-Cancer Therapies in Australia
“Termination by pharmaceutical sponsor”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.